The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of SELLAS Life Sciences Group Inc (NASDAQ: SLS) was $1.93 for the day, up 1.58% from the previous closing price of $1.9. In other words, the price has increased by $1.58 from its previous closing price. On the day, 2.77 million shares were traded. SLS stock price reached its highest trading level at $1.9499 during the session, while it also had its lowest trading level at $1.854.
Ratios:
Our analysis of SLS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.91 and its Current Ratio is at 4.91. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on July 21, 2021, initiated with a Overweight rating and assigned the stock a target price of $18.
On April 02, 2018, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $11.H.C. Wainwright initiated its Buy rating on April 02, 2018, with a $11 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 12 ’25 when VAN NOSTRAND ROBERT L bought 10,000 shares for $1.48 per share. The transaction valued at 14,800 led to the insider holds 20,400 shares of the business.
Wasman Jane bought 20,000 shares of SLS for $33,800 on May 30 ’25. The Director now owns 30,400 shares after completing the transaction at $1.69 per share. On May 22 ’25, another insider, Kalin Katherine Bach, who serves as the Director of the company, bought 20,000 shares for $1.80 each. As a result, the insider paid 36,000 and bolstered with 41,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLS now has a Market Capitalization of 241216240 and an Enterprise Value of 178664112.
Stock Price History:
The Beta on a monthly basis for SLS is 2.63, which has changed by 0.60833335 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, SLS has reached a high of $2.27, while it has fallen to a 52-week low of $0.77. The 50-Day Moving Average of the stock is 11.41%, while the 200-Day Moving Average is calculated to be 29.09%.
Shares Statistics:
SLS traded an average of 2.27M shares per day over the past three months and 2506990 shares per day over the past ten days. A total of 105.30M shares are outstanding, with a floating share count of 103.11M. Insiders hold about 2.08% of the company’s shares, while institutions hold 25.58% stake in the company. Shares short for SLS as of 1757894400 were 20889586 with a Short Ratio of 9.19, compared to 1755216000 on 29152537. Therefore, it implies a Short% of Shares Outstanding of 20889586 and a Short% of Float of 16.860001.
Earnings Estimates
SELLAS Life Sciences Group Inc (SLS) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.06 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.25 and -$0.35 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.36, with 3.0 analysts recommending between -$0.3 and -$0.41.
